Biotech startupInbrain Neuroelectronicshas received a €20 million loan from the European Investment Bank (EIB). The Catalan company is a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the ICREA institution, and a member of CataloniaBio & HealthTech.
Inbrain develops a graphene neural interface that allows more biomarkers to be detected than current devices on the market for the treatment of central nervous system (CNS) diseases. Combined with the use of big data and artificial intelligence, its technology has the ability to read and modulate brain capacity and trigger responses in personalized therapies.
Thanks to this injection of capital, the startup led by Carolina Aguilar will be able to advance in the clinical development of its R+D programs applied to the field of neurology. Ibrain works to improve diseases such as Parkinson’s, epilepsy and speech disorders.
According to CataloniaBio & HealthTech, an entity that represents companies in the biomedicine and health sector in Catalonia, the loan granted to Inbrain will allow the startup to gain flexibility for a future round of funding, which it hopes to launch in 2024.